ANDOVER, Mass., March 1, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA’s Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory Systems Device […]
Other News
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
Expands company’s financial expertise during time of growth in advance of commercial launch LISLE, Ill., March 2, 2021 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of […]
Semler Reports Record Fourth Quarter and Year End 2020 Financial Results
2020 HIGHLIGHTS compared to 2019: – Annual revenues increased by 18% – Pre-tax net income of $16.5 million, an increase of $5.8 million, or 54%, compared to $10.7 million – Net income of $14.0 million, a decrease of $1.1 million, or 7%, compared to $15.1 million (which included a $4.4 […]
Acutus Medical Receives Vizient Innovative Technology Contract
Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB) today announced that it has received an Innovative Technology contract from Vizient, Inc., the largest, member-driven healthcare performance improvement company in the United States. The […]
Neovasc Comments on Clinical Cardiology Journal Publication
VANCOUVER and MINNEAPOLIS, March 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation – A multicenter study.” The article, authored by Maayan Konigstein, M.D., Tel […]
FibroGen Provides Regulatory Update on Roxadustat
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for […]
LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]
CHF Solutions, Inc. Announces 49.5 Percent Increase in Revenue for Fourth Quarter 2020 and Provides Company Update
EDEN PRAIRIE, Minn., March 02, 2021 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the fourth quarter ended December 31, 2020. Recent Highlights Revenue for the fourth quarter of 2020 was $2 million, an increase of 49.5% compared to the prior year period Gross margin […]
Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced today it has entered into subscription agreements for a total of US$110 million via the issue of 60 million shares in a private placement led by a strategic US investor group (SurgCenter Development), at A$2.30 per share, […]
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, […]



